

# **Ganirelix Formulation**

Version 6.5	Revision Date: 06.04.2024		S Number: 190-00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014	
SECTION	1: IDENTIFICATION				
Produ	uct name	:	Ganirelix Formul	ation	
Manu	facturer or supplier's d	leta	ils		
Comp	bany	:	Organon & Co.		
Addre	Address		30 Hudson Street, 33nd floor Jersey City, New Jersey, U.S.A 07302		
Telep	hone	:	+1-551-430-6000	)	
Emer	gency telephone number	r:	+1-215-631-6999	)	
E-ma	il address	:	EHSSTEWARD	@organon.com	
Reco	mmended use of the cl	hem	ical and restriction	ons on use	
	mmended use ictions on use	:	Pharmaceutical Not applicable		
SECTION	2. HAZARDS IDENTIFIC	САТ	ION		
GHS	Classification				
Repro	oductive toxicity	:	Category 1B		
Specific target organ toxicity - : Ca			Category 1 (Bon	e marrow, Liver, Adrenal gland, spleen, Ova	

# GHS label elements

repeated exposure

GIIS label elements		
Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360Fd May damage fertility. Suspected of damaging the un- born child. H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.
Precautionary statements	:	<ul> <li>Prevention:</li> <li>P201 Obtain special instructions before use.</li> <li>P202 Do not handle until all safety precautions have been read and understood.</li> <li>P260 Do not breathe mist or vapours.</li> <li>P264 Wash skin thoroughly after handling.</li> </ul>



# **Ganirelix Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
6.5	06.04.2024	22190-00023	Date of first issue: 15.10.2014

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

#### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture
---------------------	---	---------

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ganirelix	124904-93-4	>= 0.01 -< 0.3

## **SECTION 4. FIRST AID MEASURES**

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately.
		When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water.
		Remove contaminated clothing and shoes. Get medical attention.
		Wash clothing before reuse.
		Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution.
		Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting.
		Get medical attention.
		Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and	:	May damage fertility. Suspected of damaging the unborn child.
delayed		Causes damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).



# **Ganirelix Formulation**

Version 6.5	Revision Date: 06.04.2024		DS Number: 190-00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014
Note	s to physician	:	Treat symptomati	cally and supportively.
-	5. FIREFIGHTING MEA	SU		
Suita	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
Unsu medi	iitable extinguishing a	:	None known.	
Spec fighti	ific hazards during fire-	:	Exposure to com	bustion products may be a hazard to health.
	ardous combustion prod-	:	No hazardous co	mbustion products are known
Spec ods	ific extinguishing meth-	:	cumstances and to Use water spray to	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do
	ial protective equipment efighters	:		e, wear self-contained breathing apparatus. tective equipment.
SECTION	6. ACCIDENTAL RELE	AS	E MEASURES	
tive e	onal precautions, protec- equipment and emer- y procedures	:	Follow safe hand	tective equipment. ling advice (see section 7) and personal pro- t recommendations (see section 8).
Envir	onmental precautions	:	Prevent spreading barriers). Retain and dispos	akage or spillage if safe to do so. g over a wide area (e.g. by containment or oil se of contaminated wash water. should be advised if significant spillages
	ods and materials for ainment and cleaning up	:	For large spills, p ment to keep mat be pumped, store Clean up remaining bent. Local or national posal of this mate employed in the c mine which regula	t absorbent material. rovide dyking or other appropriate contain- erial from spreading. If dyked material can a recovered material in appropriate container. Ing materials from spill with suitable absor- regulations may apply to releases and dis- erial, as well as those materials and items cleanup of releases. You will need to deter- ations are applicable.



# Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
6.5	06.04.2024	22190-00023	Date of first issue: 15.10.2014

### SECTION 7. HANDLING AND STORAGE

Technical measures	<ul> <li>See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.</li> </ul>
Local/Total ventilation	<ul> <li>If sufficient ventilation is unavailable, use with local exhaust ventilation.</li> </ul>
Advice on safe handling	<ul> <li>Do not get on skin or clothing.</li> <li>Do not breathe mist or vapours.</li> <li>Do not swallow.</li> <li>Avoid contact with eyes.</li> <li>Wash skin thoroughly after handling.</li> <li>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment</li> <li>Keep container tightly closed.</li> <li>Do not eat, drink or smoke when using this product.</li> <li>Take care to prevent spills, waste and minimize release to the environment.</li> </ul>
Hygiene measures	<ul> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.</li> <li>When using do not eat, drink or smoke.</li> <li>Wash contaminated clothing before re-use.</li> <li>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</li> </ul>
Conditions for safe storage	<ul> <li>Keep in properly labelled containers.</li> <li>Store locked up.</li> <li>Keep tightly closed.</li> <li>Store in accordance with the particular national regulations.</li> </ul>
Materials to avoid	<ul> <li>Do not store with the following product types:</li> <li>Strong oxidizing agents</li> </ul>

# SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Ganirelix	124904-93-4	TWA	0.2 μg/m3 (OEB 5)	Internal
		Wipe limit	2 µg/100 cm <sup>2</sup>	Internal

Engineering measures : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to	-
--	---



# **Ganirelix Formulation**

Version 6.5	Revision Date: 06.04.2024		lumber: -00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014
		Nc To are Op no	o open handlin tally enclosed e required. perations requ	, workers, and the environment. Ing permitted. I processes and materials transport systems ire the use of appropriate containment tech- to prevent leakage of compounds into the
Pers	onal protective equip	ment		
Resp	iratory protection		personal res ired.	piratory protective equipment normally re-
Hand	protection	4.		
M	aterial	: Ch	emical-resista	ant gloves
	emarks protection	: We If t mi We po	he work envir sts or aerosol ear a faceshie	e gloving. sses with side shields or goggles. onment or activity involves dusty conditions, s, wear the appropriate goggles. Id or other full face protection if there is a for contact to the face with dusts, mists, or
Skin :	and body protection	: We Ad tas po Us	ork uniform or Iditional body sk being perfo sable suits) to	laboratory coat. garments should be used based upon the rmed (e.g., sleevelets, apron, gauntlets, dis- avoid exposed skin surfaces. degowning techniques to remove potentially othing.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	100 °C
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable



# **Ganirelix Formulation**

Versio 6.5	on	Revision Date: 06.04.2024		S Number: 90-00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014
F	lamma	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available	9
		explosion limit / Lower bility limit	:	No data available	9
V	/apour	pressure	:	23 hPa (20 °C)	
F	Relative	e vapour density	:	No data available	9
F	Relative	e density	:	1	
S	Solubilit Wate	ty(ies) er solubility	:	completely miscil	ble
		n coefficient: n-	:	No data available	9
	octanol/ Auto-igi	nition temperature	:	No data available	9
C	Decom	position temperature	:	No data available	9
V	/iscosit Visc	y osity, kinematic	:	No data available	9
E	Explosi	ve properties	:	Not explosive	
С	Dxidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.
N	/lolecul	ar weight	:	No data available	9
	Particle Particle	characteristics size	:	No data available	9

## SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	Can react with strong oxidizing agents.
tions		
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

# SECTION 11. TOXICOLOGICAL INFORMATION

: Inhalation Skin contact



# Ganirelix Formulation

Version Revision Date: 6.5 06.04.2024

SDS Number: 22190-00023 Date of last issue: 26.09.2023 Date of first issue: 15.10.2014

Ingestion Eye contact

## Acute toxicity

Not classified based on available information.

#### **Components:**

### Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg administration)

#### Skin corrosion/irritation

Not classified based on available information.

### Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

### Ganirelix:

Species	:	Rabbit
Result	:	Mild eye irritation
Method	:	Draize Test

### Respiratory or skin sensitisation

### Skin sensitisation

Not classified based on available information.

### **Respiratory sensitisation**

Not classified based on available information.

## Components:

#### Ganirelix:

Test Type	:	Maximisation Test
Species	:	Guinea pig
Result	:	negative

### **Chronic toxicity**

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

#### Ganirelix:

Test Type: reverse mutation assay Test system: Escherichia coli





Version 6.5	Revision Date: 06.04.2024		OS Number: 190-00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014
			Result: negative	
			Test Type: in vitro Test system: Chi Result: negative	o assay nese hamster ovary cells
Genc	otoxicity in vivo	:	Test Type: In vive Species: Mouse Application Route Result: negative	o micronucleus test e: Intravenous
	n cell mutagenicity - ssment	:	Weight of eviden cell mutagen.	ce does not support classification as a germ
	inogenicity lassified based on availa	able	information.	
-	oductive toxicity damage fertility. Suspec	ted o	of damaging the ur	nborn child.
<u>Com</u>	ponents:			
<b>Gani</b> Effec	<b>relix:</b> ts on fertility	:	Species: Rat Application Route	e Treatment: 13 Weeks 0.1 μg/kg
			Species: Rat, fen Application Route Duration of Single Fertility: LOAEL:	e: Subcutaneous e Treatment: 8 Weeks
			Test Type: Fertili Species: Monkey Application Route Fertility: NOAEL: Result: Effects or	e: Subcutaneous 0.02 mg/kg body weight
Effec ment	ts on foetal develop-	:	Species: Rat, fen Application Route	e: Subcutaneous xicity: LOAEL: 10 μg/kg
			Test Type: Embr Species: Rabbit, Application Route	



# **Ganirelix Formulation**

sion	Revision Date: 06.04.2024		S Number: 190-00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014
			Embryo-foetal Result: Embryo	toxicity: LOAEL: 30 μg/kg p-foetal toxicity
Repro sessn	oductive toxicity - As- nent	:	ity, based on a	of adverse effects on sexual function and fen nimal experiments., Some evidence of adver elopment, based on animal experiments.
	<b>- single exposure</b> assified based on avai	lable	information.	
	- repeated exposure			
Cause			marrow, Liver, A	Adrenal gland, spleen, Ovary) through prolon
Com	oonents:			
Ganir	elix:			
	sure routes	:	Ingestion	
-	et Organs ssment	:		Liver, Adrenal gland, spleen, Ovary le to organs through prolonged or repeated
Rene	ated dose toxicity			
-	oonents:			
Ganir				
			Det	
Speci	es	•	Rat	
Speci NOAE		:	Rat 0.02 ma/ka	
Speci NOAE LOAE	EL	:	Rat 0.02 mg/kg 2 mg/kg	
NOAE LOAE Applic	EL EL cation Route	:	0.02 mg/kg 2 mg/kg Subcutaneous	
NOAE LOAE Applic Expos	EL EL cation Route sure time		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months	
NOAE LOAE Applic Expos	EL EL cation Route		0.02 mg/kg 2 mg/kg Subcutaneous	
NOAE LOAE Applic Expos Targe	EL EL cation Route sure time et Organs		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow	
NOAE LOAE Applic Expos	EL EL cation Route sure time et Organs es		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months	
NOAE LOAE Applic Expos Targe Speci LOAE	EL EL cation Route sure time et Organs es		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female	
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos	EL EL cation Route sure time et Organs es EL cation Route sure time		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months	
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos	EL EL cation Route sure time et Organs es EL cation Route		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months	gland, spleen, Ovary
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci	EL EL cation Route sure time et Organs es EL cation Route sure time et Organs es		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal	
NOAE LOAE Applic Expos Targe Speci LOAE Speci LOAE	EL EL cation Route sure time et Organs EL cation Route sure time et Organs es		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal Mouse, male 3 mg/kg	
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci LOAE Applic	EL EL cation Route sure time et Organs es EL cation Route sure time et Organs es EL cation Route		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal Mouse, male 3 mg/kg Subcutaneous	
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci LOAE Applic Expos	EL EL cation Route sure time et Organs EL cation Route sure time et Organs es		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal Mouse, male 3 mg/kg	gland, spleen, Ovary
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci LOAE Applic Expos	EL EL cation Route sure time et Organs es EL cation Route sure time et Organs es EL cation Route sure time sure time sure time		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal Mouse, male 3 mg/kg Subcutaneous 3 Months	gland, spleen, Ovary
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Applic Expos Targe	EL EL cation Route sure time et Organs es EL cation Route sure time et Organs es EL cation Route sure time et Organs es sure time et Organs		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal Mouse, male 3 mg/kg Subcutaneous 3 Months Liver, Adrenal	gland, spleen, Ovary
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci NOAE Applic	EL EL cation Route sure time et Organs es EL cation Route sure time et Organs es EL cation Route sure time et Organs es EL cation Route sure time et Organs		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal Monkey 2.5 mg/kg Subcutaneous	gland, spleen, Ovary
NOAE LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci LOAE Applic Expos Targe Speci NOAE Applic	EL EL cation Route sure time et Organs es EL cation Route sure time et Organs es EL cation Route sure time et Organs es EL cation Route sure time et Organs		0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal Mouse, male 3 mg/kg Subcutaneous 3 Months Liver, Adrenal Monkey 2.5 mg/kg Subcutaneous 6 Months	gland, spleen, Ovary



# Ganirelix Formulation

#### Aspiration toxicity

Not classified based on available information.

#### Experience with human exposure

### **Components:**

#### Ganirelix:

Inhalation

: Symptoms: The most common side effects are:, vaginal bleeding, Headache, Abdominal pain, Nausea, ectopic pregnancy, miscarriage

## **SECTION 12. ECOLOGICAL INFORMATION**

#### Ecotoxicity

## Components:

#### Ganirelix:

Ecotoxicology Assessment		
Acute aquatic toxicity	:	No data available

Chronic aquatic toxicity	:	No data available
--------------------------	---	-------------------

# Persistence and degradability No data available Bioaccumulative potential

No data available

# Mobility in soil

No data available

## Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

## **SECTION 14. TRANSPORT INFORMATION**

#### UNRTDG UN number

: Not applicable



# **Ganirelix Formulation**

Version 6.5	Revision Date: 06.04.2024	 DS Number: 190-00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014
Class Subs Pack Labe	sidiary risk Sing group	 Not applicable Not applicable Not applicable Not applicable Not applicable no	
IATA UN/II Prop Class Subs Pack Labe Pack aircra Pack	A-DGR D No. er shipping name s sidiary risk sing group els sing instruction (cargo	Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable	
UN n Prop Class Subs Pack Labe EmS	sidiary risk ing group	 Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable	

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

## **National Regulations**

ADG		
UN number	: N	lot applicable
Proper shipping name	: N	lot applicable
Class	: N	lot applicable
Subsidiary risk	: N	lot applicable
Packing group	: N	lot applicable
Labels	: N	lot applicable
Hazchem Code	: N	lot applicable

### Special precautions for user

Not applicable

## **SECTION 15. REGULATORY INFORMATION**

#### Safety, health and environmental regulations/legislation specific for the substance or mixture

Therapeutic Goods (Poisons	:	No poison schedule number allocated (Please use the original
Standard) Instrument		publication to check for specific uses, specific conditions or
		threshold limits that might apply for this chemical)



# **Ganirelix Formulation**

Version 6.5	Revision Date: 06.04.2024	SDS Number: 22190-00023	Date of last issue: 26.09.2023 Date of first issue: 15.10.2014			
Prohi	ibition/Licensing Requi	irements	: There is no applicable prohibition, authorisation and restricted use requirements, including for carcino- gens referred to in Schedule 10 of the model WHS Act and Regula- tions.			
The components of this product are reported in the following inventories:						
AICS	5	: not determin	ned			
DSL		: not determir	ned			
IECS	C	: not determin	led			

## SECTION 16: ANY OTHER RELEVANT INFORMATION

#### Further information

Revision Date Sources of key data used to compile the Safety Data Sheet	:	06.04.2024 Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Date format	:	dd.mm.yyyy

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evalua-



# **Ganirelix Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
6.5	06.04.2024	22190-00023	Date of first issue: 15.10.2014

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN